Holds approvals for seven infectious disease diagnostic products
Expands push into the global diagnostics market

GC Green Cross MS said on Nov. 18 that it had received export approval from the Ministry of Food and Drug Safety for its rapid and molecular diagnostic kits for hantavirus.


The company received export approval for its rapid hantavirus diagnostic kit on Oct. 30 and subsequently secured approval for its PCR-based molecular diagnostic kit on Nov. 12.

GC Green Cross MS's rapid and molecular diagnostic kits for hantavirus. GC Green Cross MS

GC Green Cross MS's rapid and molecular diagnostic kits for hantavirus. GC Green Cross MS

View original image

GC Green Cross MS currently holds approvals for seven infectious disease diagnostic products: six for export, including four dengue diagnostic reagents, one chikungunya diagnostic reagent, and one mpox virus diagnostic reagent, and one malaria diagnostic reagent for the domestic market. With the addition of its rapid and molecular diagnostic kits for hantavirus, the company has expanded its portfolio.



GC Green Cross MS plans to continue the research and development and commercialization of diagnostic products for major infectious diseases. A company official said, "We will continue to research, develop, and commercialize diagnostic products for major infectious diseases, and leverage our accumulated overseas sales network to expand the countries and product categories we serve, translating this into revenue growth for our global diagnostics business." 


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing